We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 14 juni 2018

The Lancet: [News] 2018 ASCO Annual Meeting

[News] 2018 ASCO Annual Meeting
A first-in-human phase 1 multicentre trial from the German Neurooncology Working Group by Michael Platten (Mannheim University Hospital, Mannheim, Germany) and colleagues showed that vaccination with a peptide targeting the IDH1R132H mutation in malignant astrocytomas is safe, with encouraging antitumour activity. In the NOA-16 trial, 32 patients with IDH1R132H-mutant astrocytomas who had completed chemoradiotherapy received vaccinations for 32 weeks (29 received all eight vaccinations), in addition to topical imiquimod and maintenance temozolomide.
Read more

[News] EMA restricts use of anti-PD-1 drugs for bladder cancer
The European Medicines Agency (EMA) has recommended restricting the use of pembrolizumab and atezolizumab as first-line treatments for urothelial cancer.
Read more

[News] Machine learning model in melanoma
Findings from a new study have shown that a machine-learning model can detect melanoma with greater accuracy than a group of dermatologists shown the same set of images.
Read more

[Comment] Malignant pleural effusions: will PROMISE make its name true?
One of the major challenges for chest physicians is to select the optimal treatment for patients who present with symptomatic malignant pleural effusion. Approximately 50% of patients with a malignancy develop complaints of dyspnoea related to a pleural effusion in the course of their disease. Most of these patients present with advanced disease and are in their last stage of life. To alleviate symptoms, different treatment options are available. A single pleural drainage is a simple procedure and will indicate whether a patient will benefit from repeated procedures in case of recurrence.
Read more

[Comment] Negative but not futile: MAGE-A3 immunotherapeutic for melanoma
Vaccines are one of the most effective tools that modern medicine can use against many common infectious diseases. Although cancer-associated antigens often trigger an immune response, the development of effective vaccines for cancer has been a lengthy and complicated process. Effective antigen presentation to the immune system requires an antigen fragment to be bound to the groove of the MHC class I protein on the antigen-presenting cell and be effectively presented to a matching T-cell receptor on a naive CD8 T cell along with a costimulatory signal.
Read more